Orchard Therapeutics Prices Initial Public Offering
Summary
Orchard Therapeutics plc (Nasdaq: ORTX), a biopharmaceutical company dedicated to improving the conditions of patients with serious and life-threatening rare diseases through autologous ex vivo gene therapies, priced its initial public offering in the United States.Orchard’s ADSs began trading on The Nasdaq Global Select Market on October 31, 2018, under the ticker symbol “ORTX.”The gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Orchard, are expected to be $200.00 million, excluding any exercise of the underwriters’ option to purchase additional ADSs.Orchard Therapeutics is an integrated commercial-stage biopharmaceutical company dedicated to treating patients with serious and life-threatening rare diseases through innovative gene therapies.Its advanced portfolio of autologous ex vivo gene therapies targets serious and life-threatening rare diseases, initially primary immune deficiencies, neurometabolic disorders and hemoglobinopathies.